tetano
Editor, Senior Moderator
Vaccine. 2010 Sep 15. [Epub ahead of print]
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the vaccine adverse events reporting system, United States, October 1, 2009-January 31, 2010.
Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, Lewis P, McNeil MM, Bryant M, Singleton J, Martin D, Destefano F.
Immunization Safety Office, Division of Health Care Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, United States.
Abstract
The United States (US) influenza A (H1N1) 2009 monovalent (2009-H1N1) vaccination program began in October 2009. Reports to the vaccine adverse event reporting system (VAERS), a US spontaneous reporting system, were reviewed to identify potential rare events or unusual adverse event (AE) patterns after 2009-H1N1 vaccination. The adverse event profile after 2009-H1N1 vaccine in VAERS (over 10,000 reports) was consistent with that of seasonal influenza vaccines, although the reporting rate was higher after 2009-H1N1 than seasonal influenza vaccines, this may be, at least in part, a reflection of stimulated reporting. Death, Guillain-Barr? syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered).
PMID: 20850534 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20850534
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the vaccine adverse events reporting system, United States, October 1, 2009-January 31, 2010.
Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, Lewis P, McNeil MM, Bryant M, Singleton J, Martin D, Destefano F.
Immunization Safety Office, Division of Health Care Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, United States.
Abstract
The United States (US) influenza A (H1N1) 2009 monovalent (2009-H1N1) vaccination program began in October 2009. Reports to the vaccine adverse event reporting system (VAERS), a US spontaneous reporting system, were reviewed to identify potential rare events or unusual adverse event (AE) patterns after 2009-H1N1 vaccination. The adverse event profile after 2009-H1N1 vaccine in VAERS (over 10,000 reports) was consistent with that of seasonal influenza vaccines, although the reporting rate was higher after 2009-H1N1 than seasonal influenza vaccines, this may be, at least in part, a reflection of stimulated reporting. Death, Guillain-Barr? syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered).
PMID: 20850534 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20850534